Contineum Therapeutics Inc (CTNM)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$9.39+0.64%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put CTNM beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Achieve positive cash flow from operations: Comparison needs review.
View ThesisExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 60% in its worst 12-month stretch.
View RiskContineum’s PIPE-791 clinical development for IPF and chronic pain is the central bet, but earnings remain unprofitable. The latest quarter beat on GAAP EPS, though the desk provides no revenue-growth trajectory. Reported GAAP EPS was -0.4 versus consensus of -0.46. No clean valuation multiple is available, so the peer comparison cannot define what growth is priced in. The market is pricing in more growth than the desk forecasts, leaving expectations full. A Phase 2 trial miss threatens PIPE-791’s clinical development. The next-quarter miss probability is 35%. Peer multiples imply a price about 51% above where it trades. The thesis is on watch because the operating-cash-flow comparison needs review. This read is provisional.
Trailing returns as of 2026-10-30. CTNM is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 9 analysts currently covering CTNM (as of Oct 2026).
Based on 3 Wall Street analysts offering 12-month price targets for CTNM in the last 4 months.
Continue this research
Compare CTNM with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CTNM Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put CTNM next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance PIPE-791 clinical development for IPF and chronic pain
Bristol Myers trial win supports CTNM's clinical development.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $9.39
The last 12 months of price, then the range of analyst 12-month targets from today’s $9.39.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Advance PIPE-791 clinical development for IPF and chronic pain
Phase 2 trial miss impacts clinical development for IPF.
